Objectives Our objectives were to investigate the possible effects of temperature and light on the stability of dopamine and dobutamine continuous infusions over 24 h when prepared in a variety of dilution vehicles. Methods Syringe-driver infusion apparatuses were set up for dopamine and dobutamine diluted with either 0.9% sodium chloride (NaCl) or 5% glucose delivering 3 and 5 lg/kg/min, respectively, via 206-cm extension sets. All infusions were prepared for a neonate weight of 1 kg. Infusions were run over 24 h with approximately half the tubing within an incubator set at 35°C. Cyclic voltammetry was used to monitor the concentration of the inotrope within the syringe and at the end of the extension set, both initially and after 24 h. Results The variation in the concentration of dopamine and dobutamine in the vials (n = 6) was 3.58 and 1.22%, respectively. This variation increased to 10.88% for dopamine and 5.76% for dobutamine in the syringe. After 24 h, a significant reduction in the concentration of dopamine was observed at the end of the extension set when prepared in 0.9% NaCl versus 5% glucose (p \ 0.001; n = 6-7) and in dobutamine when prepared in 0.9% NaCl (p \ 0.001; n = 6-7). No differences in the concentration of dopamine prepared in 0.9% NaCl were observed after 24 h in lightexposed and light-protected extension sets (n = 6-7).
Introduction
Previous literature has reported that hypotension develops in 20-50% of all neonates admitted to neonatal intensive care units (NICUs) and is caused by conditions including patent ductus arteriosus or sepsis [1, 2] . Hypotension leads to inadequate organ perfusion and is thought to cause detrimental effects such as poor long-term neurodevelopment and associated increases in mortality [1] [2] [3] . Preterm neonates with hypotension are particularly vulnerable to brain injury given the delicate sensitivity of developing cranial tissue to perfusion inadequacies [4] . Therefore, it is crucial that these patients are treated effectively to minimise the debilitating consequences. Inotropes, drugs that raise mean arterial pressures (MAP) by either improving myocardial contractility or increasing systemic vascular resistance, are commonly used to treat neonatal hypotension [2] [3] [4] [5] [6] . The most commonly used are dopamine and dobutamine [2, 3, 7] , which are administered intravenously as a continuous infusion by syringe drivers, which are changed every 24 h. Within our local tertiary neonatal unit, rapid swings in MAP have been observed between infusions. This could potentially lead to a reduction in blood flow to the germinal matrix in the lateral ventricles of the brain, which can cause ischaemia. Consequent reperfusion of this region as a result of a sudden rise in MAP can rupture these ischaemic blood vessels and cause intraventricular haemorrhage, which is associated with poor neurodevelopment [8] [9] [10] .
The rapid changes in MAP observed between infusions can be attributed to a number of causes, such as variations in inotrope preparation, as dilution is required; dead space in infusion lines; or the influence of multiple drugs entering through the same line and reducing observed inotrope delivery. However, such changes are regularly observed in patients receiving single or multiple inotropes, which suggests the underlying cause may be associated with the availability of the inotrope for therapeutic effect during the infusion rather than mode of delivery. One potential explanation for this observation is the stability of the drug. A limited number of studies have examined the stability of dopamine and dobutamine; they have found that light and temperature appear to be dominant factors influencing stability [11] [12] [13] [14] [15] [16] . However, most of these studies were not conducted on clinical doses or in environments that match ward settings.
The aim of this study was to investigate how environmental conditions (light and temperature) and vehicle (0.9% sodium chloride [NaCl] and 5% glucose) influence the stability of dopamine and dobutamine in a clinical laboratory model designed to mimic neonatal ward conditions.
Methods

Preparation of the Inotrope Infusion Solutions
Vials of 40 mg/ml dopamine hydrochloride (Mercury Pharmaceuticals, Dublin, Ireland) or 12.5 mg/ml dobutamine hydrochloride (Wockhardt, Wrexham, UK) were prepared in either 0.9% NaCl or 5% glucose to a concentration of 0.6 mg/ml. Dilutions in the vials were carried out using 1-ml syringes as conducted in the NICU. The weight of neonates varies in the NICU; however, we assumed a baby with a body weight of 1 kg for the preparation of inotrope infusions. Infusion solutions were delivered at 3 lg/kg/min for dopamine and 5 lg/kg/min for dobutamine as recommended by the British National Formulary for Children (BNFC) as a starting dose prescribed for a neonate weighing 1 kg [17] .
Evaluating the Stability of an Inotrope Infusion in a Laboratory Clinical Model
A small aliquot of the infusion solution was obtained to calculate the initial concentration of either dopamine or dobutamine. To simulate ward conditions, 50-ml syringes (Terumo, Lagana, Philippines) containing either 0.6 mg/ml dopamine or dobutamine were driven by a NIKI T34 syringe pump (Caesarea Medical Electronics, Lichtenstein, Germany) set to run continuously for 24 h at the flow rate determined by the BNFC. The syringe (kept at room temperature, 21°C) was connected to a 206-cm extension set (Alaris, Carefusion UK Ltd, Basingstoke, UK) that terminated to a 10-cm bifurcated minibore extension set (Codan, Santa Ana, CA, USA) and a 21-G needle. The needle pierced through parafilm, which acted as a lid for the 15-ml conical centrifuge tube (Thermo Fisher Scientific, Walthan, MA, UK) that was used to collect the infusion solution over the 24-h period. Approximately half of the tubing and collecting tube were placed in a compact incubator (Thermo Fisher Scientific) set at 35°C (Fig. 1) . This is the maximum neonatal incubator temperature according to the temperature protocol routinely used in the local neonatal unit. After 24 h, a second aliquot was obtained from the remaining solution within the syringe (Fig. 1b, location A) and from the 15-ml conical centrifuge tube (Fig. 1c, location B) . The concentrations of aliquot samples were analysed using cyclic voltammetry. To eliminate any temperature variation that may affect cyclic voltammetry responses, a one-in-ten dilution was used for the analysis of each sample. The electrochemical analyser (CH Instruments, Inc., Austin, TX, USA) employed a three-electrode system, where a 3-mm glassy carbon electrode served as the working electrode, an Ag|AgCl electrode served as the reference electrode, and a platinum wire was used as a counter electrode. A scan rate of 50 mV/s was used for each of the cyclic voltammetry studies.
Data Analysis
From each cyclic voltammogram, we recorded the oxidation peak current from the initial sample (measured 30 min following preparation) and those collected at location A and B after 24 h. The current was converted to concentration of dopamine and dobutamine using calibration responses obtained using standards at concentrations reflective of those observed clinically. These data were statistically analysed using one-way paired analysis of variance (ANOVA) with post hoc Tukey tests.
To compare between the inotropes and vehicle solutions in which they were prepared, data were shown as the percent loss in the concentration of dopamine or dobutamine at location A and B after 24 h when compared with the initial response. These data were statistically analysed using two-way paired ANOVA with post hoc Sidak test.
Data from each trial were presented as a data point in a before-after plot to observe the trend between the varying measures. Based on British Pharmacopeia guidelines for medicines production [18] , any product greater than ±7.5% would be classed as unsuitable, and we highlight this on the graphs presented.
Results
Vial Variations and Errors in Dilution
There was a 3.58% variation in the concentration present in dopamine vials, but this was significantly lower for the dobutamine vials (1.22%, n = 6 vials). Following dilution of dopamine using a 1-ml syringe to prepare a 0.6 mg/ml solution, the variance in the concentration of dopamine and dobutamine increased to 10.88 and 5.76%, respectively (n = 6 syringe preparations).
Alterations in the Concentration of Dopamine Infusions Over 24 h
No visual changes were observed in the syringes post-infusion. The oxidation peaks of dopamine (0.4 V in 0.9% NaCl and 0.6 V in 5% glucose) in both vehicles from location A and B post-infusion were consistently lower than the initial response ( Fig. 2a, b) . When dopamine was prepared in 0.9% NaCl, a significant decrease in the concentration was observed at locations A (p \ 0.05, Tukey test) and B (p \ 0.01, Tukey test) when compared with the initial response (n = 7, Fig. 2c ). There was also a significant decrease in concentration between locations A and B when dopamine was prepared in 0.9% NaCl (p \ 0.01, Tukey test, Fig. 2c) . A similar but less dramatic trend was seen in the glucose vehicle, where the concentration of dopamine significantly decreased at location B compared with the initial response (p \ 0.05, n = 6, Fig. 2d ). All trials in both NaCl and glucose showed similar patterns, with the concentration declining from initial to location A and then location B.
Alterations in the Concentration of Dobutamine Infusions Over 24 h
No visual changes were observed in the syringes post-infusion. The oxidation peaks of dobutamine (0.4 V in 0.9% NaCl and 0.6 V in 5% glucose) in both vehicles were similar to those observed for dopamine. The amplitude of the peaks from locations A and B post-infusion were consistently lower than the initial response (Fig. 3a, b) .
When dobutamine was prepared in 0.9% NaCl, a significant decrease in the concentration was observed at locations A (p \ 0.01, Tukey test) and B (p \ 0.01, Tukey test) compared with the initial response (n = 7, Fig. 3c ). A similar effect was observed when prepared in 5% glucose: the concentration of dobutamine significantly decreased at location B compared with the initial response (p \ 0.01, Tukey test, n = 6, Fig. 3d ). There was also a significant reduction in dobutamine concentration between locations A and B (p \ 0.01, n = 6). In both NaCl and glucose, similar patterns were observed, with the concentration declining over 24 h at both locations. 
Influence of the Dilution Vehicle on the Stability of Dopamine and Dobutamine
The percentage change in concentration from initial response for each trial illustrates the magnitude of decay at locations A and B (Fig. 4) . In trials of both dopamine and dobutamine infusions, the majority showed a reduction in response from location A to B, suggesting that both temperature and light may affect the stability of both inotropes. For dopamine infusions prepared in 0.9% NaCl, there was a significant reduction in response from location A to B (p \ 0.001, Sidak test, n = 7, Fig. 4a, c) . When evaluating dopamine prepared in 0.9% NaCl compared with that prepared in 5% glucose, no differences in the concentration lost after 24 h were observed at location A (n = 6-7); however, a significantly greater concentration loss was observed in location B for dopamine syringes prepared in 0.9% NaCl compared with 5% glucose (p \ 0.001, Sidak test, n = 6-7, Fig. 4a ).
For dobutamine infusions prepared in 5% glucose, there was a significant reduction in concentration from location A to B (p \ 0.01, n = 6, Fig. 4b, d) . No significant Fig. 3 Stability data for dobutamine infusion. Cyclic voltammograms following initial measurements and after 24 h in location A (syringe) and B (end of the extension set) in a 0.9% sodium chloride (NaCl) and b 5% glucose. Overall data from multiple studies showing the concentration of dobutamine following initial measurements and after 24 h in location A and B in c 0.9% NaCl and d 5% glucose. Data shown as individual trials through a before-after plot, where n = 6-7, *p \ 0.05 and **p \ 0.01 (Tukey test) differences were observed in the degree of dobutamine concentration lost at location A and B in either 0.9% NaCl or 5% glucose syringes after 24 h (Fig. 4b) .
The majority of trials for dopamine in 5% glucose, dobutamine in 0.9% NaCl, and dobutamine in 5% glucose were within pharmaceutically acceptable tolerance levels (indicated by the grey dashed lines in Fig. 4 ) in both location A and location B. The majority of trials for dopamine in 0.9% NaCl in both location A and location B were outside pharmaceutically acceptable tolerance guidelines.
Differences in the Stability of the Inotropes in Dilution Vehicles
In syringes prepared with 0.9% NaCl, no significant difference in concentration loss over 24 h was observed in dopamine and dobutamine at location A (n = 6-7, Fig. 4c) . A significant decrease in dopamine prepared in 0.9% NaCl was observed when compared with dobutamine prepared in 0.9% NaCl at location B after 24 h (p \ 0.01, Sidak test, n = 6-7, Fig. 4c ). In 5% glucose preparations, no significant differences in the concentration were observed when comparing dopamine with dobutamine in either location A or location B over 24 h (n = 6-7, Fig. 4d ).
Influence of Light on Stability of Dopamine
Syringes Prepared in 0.9% Sodium Chloride (NaCl)
Our findings clearly indicate that dopamine infusions prepared in 0.9% NaCl are the least stable over 24 h. Therefore, we wanted to understand whether this was mainly due to heat or to light. To study this, we prepared syringes in light-sensitive (clear tubing) and light-protected (orange tubing) extension sets and syringes. Figure 5 shows there was a significant reduction in the concentration of dopamine prepared in 0.9% NaCl in the orange tubing from location A to B over 24 h (p \ 0.05, Sidak Test, n = 6, Fig. 5 ). Overall, there was no significant difference between the degree of concentration loss observed at locations A and B over 24 h in the clear or orange tubing (n = 6-7, Fig. 5 ).
Discussion
Variability in the Vials and During Infusion Preparation
We observed greater variability between vials in the concentration of dopamine than in dobutamine. This increased variation was significantly enhanced following preparation of the syringe for infusion of both inotropes. The resultant variation in the concentration of the dopamine infusion was already significantly greater than the acceptable pharmaceutical tolerance limits. The variation in the dopamine vials was most likely due to the smaller dose/volume used in vial preparation when compared with dobutamine, which introduces the opportunity for more error when preparing infusions and diluting. Measuring inotrope concentration at every step from vial to infusion highlights the degree of error introduced in each step prior to delivery of the drug. This ultimately leads to inconsistency in the resulting clinical dose delivered to a neonate. It is widely acknowledged that preparation of medication in clinical practice is liable to a degree of error that can result in ill-prepared doses. Therefore, much work has gone into developing strategies to standardise the clinical preparation of medications [19, 20] . However, such preparation errors must be considered when titrating doses between infusion changes.
Differences in the Stability of Inotropes Following 24-h Infusion
The results illustrated in Figs. 2 and 3 suggest that both dopamine and dobutamine concentrations decrease over 24 h at both the syringe (location A) and at the end of the infusion line (location B). These decreases are also irrespective of the dilution vehicle in which they are prepared. While it is well known that catecholamines undergo oxidation and their stability is limited [21] , the drug instibility demonstrated in this work would not be anticipated as antioxidant preservatives are added to the intropes during manufacturing. However, our findings indicate this is still not sufficient to prevent decreases in concentration with dopamine and dobutamine. Looking solely at the concentration observed at 24 h from locations A and B relative to the initial prepared syringe provides limited information on the true clinical impact, as-in most instances-the loss is \0.1 mg/ml over 24 h because of the robust nature of the measurement. To gain insight into whether such changes vary, the percentage change in the concentration from the initial level was obtained so the differences in the dilution vehicle and type of inotrope could be obtained. Figure 4 shows that dopamine is significantly more stable when prepared in 5% glucose than when in 0.9% NaCl and that dobutamine is more stable than dopamine when both are prepared in 0.9% NaCl. Overall, this indicates dobutamine is more stable than dopamine in our ward-stimulated conditions and that inotropes are more stable in 5% glucose than in 0.9% NaCl. The enhanced stability of dobutamine under all investigated conditions may be due to its larger molecular weight and chemical structure, which can resist oxidation, when compared with dopamine. More interesting within our study was the finding that inotropes are more stable in glucose than in NaCl. This has not been shown previously; however, this may be because previous studies have predominately all used glucose as the vehicle for inotrope preparation or have only focused on one type of vehicle when investigating stability [15, 16] . Why preparation in glucose provides more stability to the inotrope infusion is unknown, but it may be associated with creating a more viscous solution and/or varying pH levels, thereby restricting diffusion of the inotropes and preservatives during infusion.
Within our clinical model, the ability to record inotrope concentrations at locations A and B provided insight into the factors that decrease stability. At location A, which represents the syringe, the temperature was the same, indicating that light makes the significant contribution to the loss of stability. However, at location B, where half of the extension set is placed within the incubator, both light and temperature are responsible for the changes in concentrations. In all trials, a decrease in concentration was observed at location B compared with location A. All trials showed a loss in concentration of the inotrope at location A after 24 h. At location B, the loss in concentration after 24 h was between approximately 5 and 10% from initial in all conditions (2.7-2.85 lg/kg/min for dopamine and 4.5-4.75 lg/kg/min for dobutamine) bar that of dopamine in 0.9% NaCl, where losses were between 10 and 35% (1.95-2.7 lg/kg/min).
Our data indicate that light does influence the stability of the inotropes, but elevated temperature has a greater effect on stability. Exposure to light is thought to be one of the dominating stability factors [14, 15, 22] ; however, in our study, no differentiation in the stability of inotropes in varying dilution vehicles was seen at location A after 24 h. More importantly, we observed no significant differences in the concentration of dopamine in 0.9% NaCl at location A and B after 24 h in clear and orange tubing. Previous studies have also shown that dopamine is stable in differing types of light [23] .
This would indicate that temperature plays a pivotal role in altering the stability of the inotropes over a 24-h infusion. Given this, it would be interesting to note whether neonates undergoing hypothermia therapy for hypoxic ischaemic encephalopathy experienced similar reductions or fluctuations in MAP towards the end of a 24-h inotrope infusion as the evaluated temperature of the incubator would be negated. Other factors that could explain the potential loss in dopamine and dobutamine concentrations may be oxygen levels causing oxidation of inotropes or adsorption/leaching of the drug onto the syringe and extension set tubing.
Despite the substantial efforts made to simulate neonatal ward conditions as accurately as possible in a laboratory setting, a few experimental design limitations can affect interpretation of the data. These include the nature of the incubator used, which does not allow for maximal light, as used on the neonatal ward, thereby underestimating the degree of degradation. Second, the collection tube remained in the incubator for the full 24 h, thereby overestimating the degree of degradation. Overall, these two limitations may compensate for one another; the observed tends in our data more likely reflect the stability of the inotropes, albeit the precise levels observed may not be accurate.
Another important consideration is that our study was a very simple clinical model that did not fully mimic drug delivery of inotropes, as they are often co-administered with other compounds, formulations, or parenteral nutrition. The latter, which is more common, is of significance as these formulations often contain NaCl, which could potentially alter the stability of dopamine no matter which dilution vehicle was used. Another important factor to consider is that the data presented highlight that impact of changes in the accuracy of concentration due to environmental factors and medicine preparation. Such factors in combination can significantly reduce the delivered dose compared with the actual dose, which may be why most infusions are titrated during delivery. Significant clinical consideration needs to be given to the impact of these factors during delivery of inotropes, particularly during times of syringe changes.
Conclusion
Overall, the stability study showed that, during a 24-h continuous infusion under conditions such as exposure to light and 35°C temperature as experienced in the NICU, dobutamine is a more stable inotrope than dopamine and 5% glucose is a more stable vehicle than 0.9% NaCl. These findings may indicate why particular fluctuations in MAP are observed during infusion changeovers. Clinical staff might want to take the results of our study into account when prescribing inotropes in the future, as 5% glucose might be the preferred dilution vehicle, or dobutamine the preferred inotrope if 0.9% NaCl is the necessary dilution vehicle.
